Live Breaking News & Updates on மைலன் ஆய்வகங்கள் லிமிடெட்|Page 1
Stay updated with breaking news from மைலன் ஆய்வகங்கள் லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Advertisement The Current State of Precedential Opinions and Denials of Institution at the USPTO Patent Trial and Appeal Board: Part 1 Wednesday, May 5, 2021 This article is the first of three that will discuss the USPTO Patent Trial and Appeal Board (“Board”)’s use of Precedential Opinions as guidance when exercising discretion whether to institute petitions for post-grant proceedings, inter partes reviews (IPRs) and post-grant reviews (PGRs). In particular, this article addresses the precedential decision, Apple Inc. v. Fintiv, Inc., [1] which outlines six factors for the Board to consider when denying a petition under 35 U.S.C. § 314(a) based on a parallel proceeding. The second article will discuss how the Board can exercise discretion to deny institution under § 325(d) if the petition relies on the same or similar prior art/arguments presented during examination, using the test outlined in ....
To print this article, all you need is to be registered or login on Mondaq.com. I recently wrote an article (NHK-Fintiv Rule Challenges Look Futile at Federal Circuit) about a Federal Circuit decision that dismissed Mylan s appeal of a PTAB decision that denied institution of an IPR. The Federal Circuit concluded that although judicial review is available by petition for mandamus and the Federal Circuit may consider Mylan s request for mandamus, there is no reviewability of the Director s exercise of his discretion to deny institution except for colorable constitutional claims. Mylan Laboratories Ltd. v. Janssen Pharmaceutica. N.V., No. 2021-1071, slip op. at 12 (Fed. Cir. March 12, 2021) ....
COVID-19: Remdesivir MRP slashed by half with retro-effect Spelling huge relief for lakhs of Covid-19 patients, the government has slashed the prices of the ‘life-saver’ Remdesivir injection by nearly 50 per cent, to MRP Rs 2,450 per injection now, according to official sources. | 18 April 2021 2:29 AM GMT MUMBAI: Spelling huge relief for lakhs of Covid-19 patients, the government has slashed the prices of the life-saver Remdesivir injection by nearly 50 per cent, to MRP Rs 2,450 per injection now, according to official sources. In a missive late on Friday, the Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, NPPA - Advisor (Costs) N.I. Chowdhury has ordered all pharma companies to comply with the revised norms with immediate and retrospective effect. ....
Govt slashes Remdesivir MRP by half, with retro-effect Sat, Apr 17 2021 12:51 IST | 3 Views
Mumbai, April 17 : Spelling huge relief for lakhs of Covid-19 patients, the government has slashed the prices of the life-saver Remdesivir injection by nearly 50 per cent, to MRP Rs 2,450 per injection now, according to official sources. In a missive late on Friday, the Ministry of Chemicals & Fertilisers, Department of Pharmaceuticals, NPPA - Advisor (Costs) N.I. Chowdhury has ordered all pharma companies to comply with the revised norms with immediate and retrospective effect. Based on the Form-V furnished regarding voluntary reduction in Maximum Retail Price (MRP) of Remdesivir, Manufacturers/Marketers of the Remdesivir are hereby directed to implement the revised MRP throughout the distribution chain w.e.f. 15.04.2021, irrespective of the batch numbers, the stern notification said. ....
Spelling huge relief for lakhs of Covid-19 patients, the government has slashed the prices of the life-saver Remdesivir injection by nearly 50 per cent, to MRP Rs 2,450 per injection now, according to official sources. In a missive late on Friday, the Ministry of Chemicals & Fertilisers, Department of Pharmaceuticals, NPPA - Advisor (Costs) N.I. Chowdhury has ordered all pharma companies to comply with the revised norms with immediate and retrospective effect. Based on the Form-V furnished regarding voluntary reduction in Maximum Retail Price (MRP) of Remdesivir, Manufacturers/Marketers of the Remdesivir are hereby directed to implement the revised MRP throughout the distribution chain w.e.f. 15.04.2021, irrespective of the batch numbers, the stern notification said. ....